ASTRO highlights Winship study showing increased failure-free survival in prostate cancer

October 23, 2020

A study from Winship Cancer Institute of Emory University (Winship) has the potential to change how patients whose prostate cancer recurs after prostatectomy are treated. The study will be featured in both the plenary session and press program of the American Society for Radiation Oncology (ASTRO) Annual Meeting on Monday, October 26.

The Emory Molecular Prostate Imaging for Radiotherapy Enhancement, or EMPIRE-1 trial (
The phase II/III trial was led by Winship radiation oncologist and prostate cancer specialist Ashesh B. Jani, MD, MSEE, FASTRO, and Winship nuclear radiology specialist David M. Schuster, MD, FACR. The trial enrolled 165 patients whose cancer recurred after having undergone prostatectomies. One group received radiation therapy based on conventional imaging. The other group received treatment that was finalized based on imaging with the fluciclovine PET radiotracer. Those whose treatment was adjusted according to the results of the advanced molecular imaging showed an improvement in the cancer control end point.

"At three years, the group getting treatment guided by PET fluciclovine had a 12 percent better cancer control rate, and this persisted at four years as well, with a 24% improvement," says Jani. "We think the improvement was seen because the novel PET allowed for better selection of patients for radiation, better treatment decisions, and better radiation target design."

The study, "

"We knew that diagnostic performance of this PET radiotracer was better than conventional imaging. We also knew it changes management. But did it change management in the right direction? This study has allowed us to take it one step further and determine if using this imaging influences outcomes for the better. And it does," says Schuster.

The study used a type of PET known as fluciclovine (fluorine-18, or 18F) which was invented by a multidisciplinary team at Emory and is now commercialized by Blue Earth Diagnostics.

Fluciclovine was originally developed by Mark M. Goodman, PhD, Winship researcher and professor of radiology and imaging sciences at Emory University School of Medicine, and colleague Timothy Shoup, PhD, currently at Massachusetts General Hospital. In 1999, Goodman, Shoup, and Winship neurosurgeon Jeffrey J. Olson, MD, published a study on the use of fluciclovine for brain tumor imaging.

Over a decade ago, researchers decided to explore if fluciclovine could also work for prostate cancer because of its low native urinary excretion. Jani and Schuster commenced a clinical trial in 2012 to determine if fluciclovine could be used to guide radiotherapy decisions and treatment volumes post-prostatectomy.

The technology was licensed to Blue Earth Diagnostics in 2014, and in 2016 the U.S. Food and Drug Administration approved the use of fluciclovine to diagnose men with recurrent prostate cancer with elevated blood levels of prostate-specific antigen after previous treatment. It is the first FDA-approved fluorinated PET radiotracer (trade name Axumin) for prostate cancer staging.

Funded by a $2.2 million grant from the National Institutes of Health, Jani and Schuster began the EMPIRE-1 trial in 2012 to further establish the role of advanced molecular imaging with fluciclovine in post-prostatectomy decision-making and treatment volumes. Jani and Schuster say the work behind this study represents the best of team science.

"The invention and development of this imaging technology speaks to the strength of collaborative science and breadth of expertise at Winship," said Winship Executive Director Walter J. Curran, Jr., MD. "This study would not have been possible without Winship's comprehensive cancer center infrastructure."

Jani and Schuster are leading another NIH-funded ($3.7 million) trial, EMPIRE-2, to investigate a newer type of advanced molecular imaging, PSMA or prostate specific membrane antigen PET. The new radiotracer targets a receptor on the surface of prostate cancer cells. Investigators hope to discover whether this newer type of PET scan could be even more effective than fluciclovine in improving cancer control for prostate cancer patients with recurring cancer.
As the National Cancer Institute (NCI)-designated comprehensive cancer center for Georgia, Winship Cancer Institute of Emory University discovers, develops and delivers some of the world's most effective ways to prevent, detect, diagnose and treat each patient's unique cancer. Leveraging the depth and breadth of Emory University and collaborations with other NCI cancer centers and leading cancer organizations, Winship is devoted to changing the way cancer is predicted, treated and survived for families throughout Georgia, the nation and the world.

Emory Health Sciences

Related Prostatectomy Articles from Brightsurf:

Cerenkov luminescence imaging identifies surgical margin status in radical prostatectomy
A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of The Journal of Nuclear Medicine.

ASTRO and AUA update joint clinical guidance for radiation therapy after prostatectomy
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) today announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.

Improved procedure for cancer-related erectile dysfunction
Melbourne surgeons have modified a minimally invasive technique to help men regain erectile function lost after prostate cancer surgery.

UBC research recommends graduated return to work after prostatectomy
UBC research cautions men recovering from a radical prostatectomy to take it easy when returning to work.

Hormonal treatment may trigger depression in men with prostate cancer
Men who receive anti-hormonal treatment after having their prostate removed are 80 percent more likely to suffer from depression than men who don't receive this treatment.

Study finds upsurge in 'active surveillance' for low-risk prostate cancer
Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative 'active surveillance' strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer
A comparison of two of the most common combination therapies for locally advanced prostate cancer show the more aggressive option is linked with a higher rate of survival.

Obese men may have higher chance of recurrence following radical prostatectomy
Among men with prostate cancer who underwent radical prostatectomy (RP), those who were obese had a higher risk of biochemical recurrence, according to data presented at the American Association for Cancer Research Special Conference Obesity and Cancer: Mechanisms Underlying Etiology and Outcomes, held Jan.

Adverse effects, quality of life of treatment vs. no treatment for men with localized prostate cancer
Two studies published by JAMA examine the adverse effects and quality of life as reported by men with localized prostate cancer who chose treatment, observation or active surveillance.

How does penis length change after prostate cancer surgery?
Many patients who have their prostate glands removed as a treatment for prostate cancer complain of shortening in the length of the penis.

Read More: Prostatectomy News and Prostatectomy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to